Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
10 matches for "Samsung Bioepis CO LTD"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Opuviz Aflibercept-Yszy | Samsung Bioepis CO LTD | BLA761350 | May 20, 2024 | |
| Byooviz Ranibizumab-Nuna | Samsung Bioepis CO LTD | BLA761202 | Sep 17, 2021 | |
| Epysqli Eculizumab-Aagh | Samsung Bioepis CO LTD | BLA761340 | Jul 19, 2024 | |
| Hadlima Adalimumab-Bwwd | Samsung Bioepis CO LTD | BLA761059 | Jul 23, 2019 | |
| Eticovo Etanercept-Ykro | Samsung Bioepis CO LTD | BLA761066 | Apr 25, 2019 | |
| Pyzchiva Ustekinumab-Ttwe | Samsung Bioepis CO LTD | BLA761373 | Jun 28, 2024 | |
| Pyzchiva Ustekinumab-Ttwe | Samsung Bioepis CO LTD | BLA761425 | Apr 30, 2025 | |
| Ontruzant Trastuzumab-Dttb | Samsung Bioepis CO LTD | BLA761100 | Jan 18, 2019 | |
| Renflexis Infliximab-Abda | Samsung Bioepis CO LTD | BLA761054 | Apr 21, 2017 | |
| Denosumab-Dssb Denosumab-Dssb | Samsung Bioepis CO LTD | BLA761392 | Oct 29, 2025 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.